Cure CLCN4 2025
Cure CLCN4 2025
Assay Genie was honored to attend and present at the 2025 Cure CLCN4 Scientific Conference, held on May 19–20 at Friends House in London and online. This annual event, now in its fourth year, brought together researchers, clinicians, industry leaders, and families to advance understanding and treatment of CLCN4-related neurodevelopmental disorders.
As a proud platinum sponsor, Assay Genie reaffirmed its long-standing support for the Cure CLCN4 community. Since 2022, we have partnered with Cure CLCN4 to provide high-quality reagents and scientific insights that empower researchers worldwide. Our sponsorship underscores our dedication to accelerating research in rare genetic conditions through collaboration and innovation.


Dr. Colm Ryan’s Presentation
Dr. Colm Ryan, CEO of Assay Genie, delivered a compelling talk highlighting the company's mission to support rare disease research. He emphasized the importance of accessible, high-quality reagents in advancing scientific discovery and shared insights into how Assay Genie's products are aiding researchers in unraveling the complexities of CLCN4-related conditions. Dr. Ryan's presentation resonated with attendees, reinforcing the critical role of industry partnerships in driving progress.

Conference Highlights
The 2025 conference featured a dynamic program, including keynote lectures, panel discussions, and the introduction of 'Lightning Talks'—short, impactful presentations by early-career researchers. These sessions fostered vibrant discussions and showcased cutting-edge research in the field. Notable speakers included Dr. Jenna Carpenter, who discussed genome editing as a future treatment avenue, and Dr. Kamal Masarweh, who presented on integrated care models for rare conditions.
Looking Ahead
Assay Genie remains committed to supporting the Cure CLCN4 community and the broader rare disease research ecosystem. We are inspired by the collaborative spirit and scientific advancements showcased at this year's conference and look forward to continuing our partnership in the pursuit of breakthroughs that improve lives.
26th May 2025
Recent Posts
-
CD25+FOXP3+CD45RA- Treg Cells and Cancer Prognosis
The Role of CD25+FOXP3+CD45RA- Treg Cells in Cancer PrognosisIntroductionRegulatory T-cells (Treg ce …1st Aug 2025 -
Understanding PIIINP Levels in Canine Liver Fibrosis
Understanding PIIINP Levels in Canine Liver FibrosisLiver fibrosis is a significant health concern i …1st Aug 2025 -
TIM-3/Gal-9 Pathway in Antiparasitic Immunity
Exploring the Role of TIM-3/Gal-9 in Antiparasitic ImmunityIntroductionThe immune system is a comple …1st Aug 2025